Skip to content

Evaluation of a Nutritional Technology for Vitamin D Absorption

Evaluation of a Lipid-based Nutritional Technology for Enhancing Vitamin D Absorption in Humans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06266702
Enrollment
26
Registered
2024-02-20
Start date
2024-03-15
Completion date
2024-05-02
Last updated
2024-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition, Healthy

Brief summary

This is a prospective, 2-group crossover, randomized, double-blind study to evaluate nutrient absorption.

Interventions

OTHERExperimental Oil with Phospholipids

Consumed on white bread

OTHERControl Polyunsaturated Oil Blend

Consumed on white bread

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult participants (18-55 years of age) * Body mass index (BMI) \<30 kg/m2 * Males and nonpregnant, nonlactating females * Free of gastrointestinal disorders that my impact nutrient absorption in the small intestine, endocrine, hepatic, renal, or bone diseases

Exclusion criteria

* Use of vitamin D or calcium supplements within 3 weeks prior to the Screening Visit. * Use of a tanning booth/lamp within 3 weeks prior to the Screening Visit. * Travel to sunny location within 3 weeks prior to the Screening Visit. * Consumption of more than 3 alcoholic drinks per day starting 48 hours before the Screening Visit. * Has an allergy or intolerance to any ingredient in the study product. * Participating in another study that has not been approved as a concomitant study by Abbott Nutrition. * Use of the following medications that may have interactions with vitamin D absorption or metabolism: * Aluminum-containing phosphate binders * Anticonvulsants * Atorvastatin * Calcipotriene * Cholestyramine * Cytochrome P-450 3A4 substrates * Digoxin * Diltiazem * Orlistat * Thiazide diuretics * Corticosteroids * Stimulant laxatives * Verapamil

Design outcomes

Primary

MeasureTime frameDescription
Vitamin D AbsorptionTime 0 to 24 HoursChange in area under the curve (AUC) of serum vitamin D for low dose in experimental versus control oil

Secondary

MeasureTime frameDescription
Vitamin D Absorption - PeakTime 0 to 48 HoursChange in Peak serum for vitamin D in experimental versus control oil
Vitamin D Absorption - AUCTime 0 to 48 HoursChange in AUC for vitamin D in experimental versus control oil

Other

MeasureTime frameDescription
Body Mass IndexVisit 1, Baseline CollectionAs calculated from height in cm and weight in kg
Adverse EventsStudy Day 1 to Study Day 7 up to 20 DaysParticipant reported adverse events during study duration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026